The FDA has updated its policy on COVID-19 testing, clarifying that manufacturers of multi-analyte respiratory panels which include SARS-CoV-2 are now eligible for Emergency Use Authorization (EUA).
The agency noted that multi-analyte panels are useful when multiple respiratory pathogens are circulating at the same time, as is expected with the upcoming flu season.
When determining whether to issue an EUA for a multi-analyte respiratory panel that includes SARS-CoV-2, the agency said it considers the clearance or approval status of diagnostics for the other analytes on the panel.
Memory
SK Hynix shifts focus in China: Shanghai out, Wuxi in
Memory
Trymax: Receives multi-system orders from a large asian based foundry
Semiconductor Equipment
Intel industry’s first mover on High NA EUV lithography system
Computing and Software
What works best for chiplets
Computing and Software
Underappreciated EU suppliers lead the semiconductor equipment market
Global Semiconductor Trends
Yole Group Viewpoint – Exploring semiconductor equipment during a geopolitically charged era
Semiconductor Equipment
Mycronic receives order for an SLX mask writer
Computing and Software
FPGA market set for steady demand growth
Compound Semiconductor
Power GaN: harnessing new horizons
Semiconductor Equipment